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Eukaryotic messenger RNA (mRNA) is modified by the addition of an
inverted guanosine cap to the 50 triphosphate. The cap guanosine and initial
transcribed nucleotides are further methylated by a series of cap methyl-
transferases to generate the mature cap structures which protect RNA
from degradation and recruit proteins involved in RNA processing and
translation. Research demonstrating that the cap methyltransferases are
regulated has generated interest in determining the methylation status of
the mRNA cap structures present in cells. Here, we present CAP-MAP:
cap analysis protocol with minimal analyte processing, a rapid and sensitive
method for detecting cap structures present in mRNA isolated from tissues
or cultured cells.1. Introduction
Eukaryotic RNA polymerase II (RNAPII)-transcribed RNAs are modified by
the addition of 7-methylguanosine to the 50 triphosphate found on the first tran-
scribed nucleotide, forming the cap structure denoted m7GpppN (N is any
nucleotide) (figure 1) [1,2]. For many short RNAPII transcripts involved in
guiding RNA processing and modification, the cap is a precursor for further
modification [3]. For pre-messenger RNA (mRNA), the cap guides transcript
processing and selection for translation via interactions with cap-binding pro-
teins, while protecting the transcript from 50–30 exonucleases [4]. Metazoan
mRNA caps additionally contain ribose methylated on the O-2 position of
the first and second transcribed nucleotides (denoted Nm), which creates a
further ‘self-mRNA’ mark, enabling innate immunity proteins to differentiate
it from unmethylated, foreign RNA [5,6]. Removal of the cap by decapping
enzymes usually directs mRNA to be degraded. Decapping is also regulated
by RNA binding proteins which promote or antagonize the recruitment of de-
capping complexes to the mRNA [7]. Thus, the cap is essential for the proper
processing, function and lifespan of an mRNA.
MammalianmRNAprocessing initiates co-transcriptionallywith the addition
of the inverted guanosine cap, catalysed by Capping Enzyme/RNA guanylyl-
transferase and 50 phosphatase (CE/RNGTT) [2,8]. The terminal cap guanosine
is methylated by RNA cap methyltransferase (RNMT) on the N-7 position and
the first two transcribed nucleotides are modified by cap-specific methyltransfer-
ases as follows: the O-2 position of the ribose of the first and second transcribed
nucleotides are methylated by Cap Methyltransferase 1 (CMTR1) and CMTR2,
RNMT
CAPAM
CMTR1
CMTR2
second transcribed nucleotide 
cap guanosine added by RNGTT 
first transcribed nucleotide  
Figure 1. mRNA cap structure. A common cap structure is depicted, including cap guanosine, the first transcribed nucleotide and the second transcribed nucleotide.
The sites of action of the capping enzymes RNGTT, RNMT, CMTR1, CMTR2 and CAPAM are indicated.
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2respectively, and if the first transcribed nucleotide is adenosine
it is methylated on the N-6 position by cap-specific adenosine
methyltransferase (CAPAM, also known as PCIF1) [9–12]
(figure 1).
The cap structure was first discovered in viral mRNA and
determined to mimic eukaryotic cellular mRNA in order to
hijack the translation machinery and evade detection by the
host innate immunity proteins [1]. From the 1970s, m7GpppNm-
pN and m7GpppNmpNm caps, as well as the
m6Am
modification, were detected in mammalian cells by chromato-
graphically separating RNAse-digested radiolabelled mRNA
and by mass spectrometry (MS) [13–19]. More recently, it has
become apparent that the capmethyltransferases are regulated
during important cellular processes including the cell cycle,
oncogenic transformation, anti-viral responses and embryonic
stem cell differentiation [20–26]. This has rejuvenated interest
in determining the relative abundance of each cap structure
and additional cap analysis techniques have been developed
[27]. First nucleotide ribose O-2 methylation and adenosine
N-6 methylation have been detected by radiolabelling the
terminal nucleotides and resolving them by two-dimensional
thin-layer chromatography (TLC) [28]. Since this method
does not require in vivo labelling, mRNA from any source
can be analysed and the method can be adapted to investigate
methylation of specific mRNAs; however, it is technically chal-
lenging and requires the use of radio-isotopes. Affinity
reagents can be used to enrich methylated nucleotides and
specific cap structures in a semi-quantitative manner.
Capped mRNA can be enriched using antibodies that
recognize m2,2,7G and m7G, although such antibodies exhibit
gene specificity whichmay be due to the cap structures present
or RNA secondary structure [24,29,30]. Recent studies have
detected internal m7G in mRNA, which compromises the
use of anti-7-methylguanosine antibodies for cap detection
[31,32]. Similarly, internal and cap-adjacent m6A have been
mapped using an anti-m6A antibody, but since internal m6A is
abundant this method requires knowledge of the transcription
start site to determine m6A-containing cap structures. [33,34].
Recombinant eIF4E can also be used as an affinity reagent for
capped mRNA although this does not specify particular cap
structures [4]. Recently, an antibody-free m6A mapping
method has been developed [35]. A cytidine deaminase fusedto the m6A-binding domain of the YTH domain was expressed
in cells, resulting in C-to-U deamination at sites adjacent to m6A
residueswhich can be detected byRNA-seq.With the advent of
nanopore sequencing, methylated nucleotides can be detected
on specific sequences and this is likely to include the first
transcribed nucleotides of the cap in the near future [36].
MS has been employed to detect various nucleotide modi-
fications, including the cap [1,37,38]. Since the first transcribed
nucleotide is expected to be Nm (ribose O-2 methylated), the
presence of m6Am is associated with cap structures. A more
accurate method for cap analysis involves detecting the cap
dinucleotide m7GpppNm, or short 50 mRNAs including this
structure. Recently, this has been used successfully to detect
cap structures derived from short RNAs, precursor tRNAs,
as well as to monitor the activities of CAPAM and the m6A
demethylase fat mass and obesity-associated protein (FTO)
on the first transcribed nucleotide of in vitro transcribed
RNA [3,25,39–41]. More recently, cellular mRNA cap struc-
tures isolated with an anti-m7G antibody have been analysed
by MS and m7GpppGmGp,
m7GpppAmGp and
m7Gpppm6Am-
Gp caps were readily detected [9]. Caps lacking first
transcribed nucleotide methylation were not detected,
indicating their rarity.
To gain a better understanding of in vivo cap regulation, we
developed an approach to determine the relative proportions
of the different mRNA cap structures using a rapid and
unbiased approach. Here, we present the CAP-MAP (cap
analysis protocol with minimal analyte processing) method
for detecting and quantifying mRNA cap structures by liquid
chromatography–mass spectrometry (LC–MS).2. Results
We developed CAP-MAP to detect and quantify the mRNA
cap structures present in cells and tissues. Specifically, the
method assesses the permutations of N-7 methylation of
the terminal cap guanosine, O-2 methylation of the first
nucleotide ribose and N-6 methylation of the first nucleo-
tide adenosine in mRNA caps from biological samples
(figure 1). Briefly, the method involves mRNA enrichment
from total cellular RNA using oligo dT affinity beads. The
select polyadenylated RNA with oligo dT  beads 
digest with
nuclease P1 
cap dinucleotide 
nucelotide 5¢ monophosphate
ARCA spike in
LC–MS 
Figure 2. Overview of RNA preparation for CAP-MAP analysis. Cellular RNA is purified on oligo dT-conjugated beads and digested with P1 nuclease to release cap
dinucleotides and nucleotide monophosphates. The synthetic cap standard, ARCA, is added to the digested nucleotides. The sample is run on a PGC column coupled
to a triple quadrupole mass spectrometer operating in negative ion mode and programmed to detect cap dinucleotides in the MRM mode.
royalsocietypublishing.org/journal/rsob
Open
Biol.10:190306
3mRNA is digested with nuclease P1, a non-specific ssRNA/
DNA nuclease, to release nucleotide 50 monophosphates
and cap dinucleotides, (m7)GpppN(m). The latter is resolved
by liquid chromatography on a porous graphitic carbon
(PGC) column and identified by negative ion electrospray
MS using multiple reaction monitoring (MRM) (figure 2).
Negative ion mode was selected because of the propensity
of nucleotides to form negative ions and for its better
signal-to-noise ratio relative to positive ion mode. MRM is
a procedure whereby, at any given moment, the first quad-
rupole/mass filter is programmed to allow through ions of
only a single m/z value (X) into the second quadrupole/col-
lision cell, where collision-induced dissociation (CID)
occurs, and the third quadrupole/mass filter is pro-
grammed to allow through ions of typically only two m/z
values (Y and Z) to the detector. In this way, ion currents
(peaks) are only recorded when an analyte that produces
a precursor ion (in this case an [M-H]− ion) of m/z X gener-
ates product ions of m/z Y and Z. This, together with the
LC retention time, provides confidence in the analyte
identification as well as great sensitivity since the mass
spectrometer is not spending time scanning irrelevant
mass ranges.2.1. LC–MS analysis of cap dinucleotides
Eleven synthetic cap dinucleotides, four obtained commer-
cially and seven custom synthesized (table 1), were used to
established retention times relative to an internal standard on
PGC liquid chromatography and to optimize MRM conditions
(mass transitions and collision energies) for their detection and
quantification (table 2). These cap dinucleotides have adeno-
sine or guanosine as the first transcribed nucleotide, thus
our method will only detect these variants and not those
with cytidine or uridine, which are also present in cells. The
internal standard was the anti-reverse cap analogue
(ARCA), which is not present in cells. ARCA has the structure
m7GO-3 mpppG, which is physically similar to but structurally
distinct from endogenous cellular caps. Duringmethod devel-
opment, we selected HyperCarb PGC as the preferred LC
column type over SeQuant ZICpHILIC because the latter
could not resolve the isobaric cap structures m7Gpppm6A
and m7GpppAm. Using PGC, we found that excellent peak
shape and low carry-over between runs (less than 0.1%)
could be obtained by using a pH 9.15 aqueous component
and maintaining the column at 45°C. Furthermore, the high
organic solvent (acetonitrile) content required for cap elution
Table 1. Synthetic cap dinucleotide standards.
cap source
GpppA NEB
m7GpppA NEB
GpppG NEB
m7GpppG NEB
Gpppm6Am synthesized
m7Gpppm6Am synthesized
GpppAm synthesized
GpppGm synthesized
m7GpppGm synthesized
m7GpppAm synthesized
m7Gpppm6A synthesized
ARCA (m7GO-3 mpppG) NEB
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4from PGC was advantageous in the electrospray ionization
process. Using the conditions described in the Materials
and methods, all 11 cap dinucleotides could be resolved by
retention time and/or MRM transitions (figure 3). To reduce
PGC column deterioration over time, leading to peak broad-
ening and increasing retention times [42,43], we adopted
some previous recommendations [43,44]. In particular, we
regularly regenerated the columns by equilibrating in 95%
methanol for between 1 h and 16 h.
To determine the linear range of detection for the cap dinu-
cleotides during LC–MS, a dilution series of 10 of the cap
dinucleotides was analysed (figure 4a,b). All cap dinucleotides
were detected in a linear range down to approximately 4 fmol,
with detection of some caps being nonlinear at lower concen-
trations. Linear regression was used to calculate the slope for
the peak area/fmol of each cap, which was later used to
convert peak area to fmol quantities for each cap (table 3).
m7GpppG and GpppGm caps are a challenge to distinguish
by LC–MS because they are isobaric, elute very closely on PGC
andproduce similar CID spectra. Fortunately, m7GpppGgener-
ates a unique product ion at m/z 635.9; thus we can detect and
quantify m7GpppG with the unique precursor→ product ion
transition of m/z 800.9→ 635.9. However, both m7GpppG and
GpppGm produce precursor→ product ion transitions of m/z
800.9→ 423.9 and 438.0. Thus, to quantify GpppGm we have
to correct for any m/z 800.9→ 423.9 and 438.0 transition ion
currents due to m7GpppG . This is possible because the ratio
of m/z 635.9 : 423.9 : 438 product ion intensities for m7GpppG
are constant. Consequently, the m/z 423.9 and 438 product
ion contributions due to m7GpppG can be back-calculated
from the m7GpppG-unique m/z 635.9 ion current. Examples
of the calculations of the concentrations of m7GpppG and
GpppGm in liver samples are shown in figure 4e.2.2. LC–MS analysis of mRNA cap dinucleotides
from liver
Having established an LC–MS protocol with synthetic cap
dinucleotides we proceeded to analyse cellular mRNA cap
structures. Digestion of cellularmRNAwith nuclease P1 results
in a mixture of cap dinucleotides, nucleotide monophosphatesand the nuclease protein. Various strategies including weak
anion exchange and precipitation protocols were trialled to
enrich and concentrate cap dinucleotides; however, these
attempts resulted in a substantial loss of sample. We were
also concerned that the enrichment methods may selectively
alter the composition of cap dinucelotides in a sample. There-
fore, we analysed cellular cap dinucleotides by LC–MS with
minimal processing by directly injecting the whole nuclease
P1 digest. Since therewas no purification of the cap nucleotides
after digestion, there was a risk that the nuclease P1 might
accumulate on the column, increasing the back pressure. How-
ever, the back pressure of the column was monitored over 100
runs and was stable at around 40 bar.
When we analysed the mRNA cap structures present in
mouse liver, wewere able to detect nine of the 11 cap dinucleo-
tides assessed (figure 5a). Importantly, we found that the
absolute ion currents recorded for the ARCA internal standard
were the samewhether or not it was injected alone or with cel-
lular mRNA samples, suggesting no detectable interference
(ion suppression) from the cellular mRNA nuclease P1 digests.
Nucleotide monophosphates make up the majority of the
nuclease P1 digests; adenosine monophosphate (AMP) eluted
before cap dinucleotides (electronic supplementary material,
figure S1).
The most common cap structures in liver mRNA were
m7GpppGm (19 fmol/µg),
m7GpppAm (4 fmol/µg) and
m7Gpppm6Am (20 fmol/µg) (figure 5a); these are the major
cap variants previously elucidated by MS and TLC of radio-
labelled nucleotides [1,28]. In line with recent observations
that m7Gpppm6Am is an abundant cap structure,
m7Gpppm6Am
constituted 75% of the caps when A was the first transcribed
nucleotide [9–12]. A number of incompletely methylated cap
structures were detected including GpppA, GpppAm,
Gpppm6Am and GpppGm, which lack cap guanosine N-7
methylation; and m7GpppA and m7GpppG, which lack ribose
O-2 methylation of the first transcribed nucleotide.
To determine the minimum input of mRNA required to
detect the different cap structures, we prepared a dilution
series of liver mRNA. Ten cap dinucleotides, including in this
experiment GpppG, were detected in 30 µg and in 15 µg
mRNA, and the three most abundant caps were reproducibly
detected in 250 ng mRNA (figure 5b,c). The concentration
(fmol µg−1) of each cap dinucleotide was consistent across a
range of inputs, when above the threshold of detection for
that cap. The consistent detection of mRNA caps and ARCA
internal standard across a range of input mRNA is further evi-
dence of insignificant ion suppression from the cellular mRNA
nuclease P1 digests.
In summary, we established CAP-MAP as a rapid, quan-
titative and relatively direct method for detecting mRNA
cap dinucleotides.2.3. CAP-MAP comparison of mRNA caps from
mammalian cells and tissues
To compare the relative cap abundancies in tissues, mRNA
samples were prepared from liver, heart, brain and activa-
ted CD8 T cells. In each sample, the most common cap
dinucleotides were m7GpppGm and
m7Gpppm6Am, which
were present at greater than 10 fmol µg−1 across all sources
(figure 6a and table 4). m7GpppAm was less common, but
always present over 0.5 fmol µg−1 mRNA. A variety of less
Table 2. Mass spectrometer settings.
compound
precursor
(m/z)
product
(m/z)
collision
energy (V)
RF lens
(V)
retention time
relative to ARCA
GpppA 771.1 408.0 36 150 0.95
GpppA 771.1 424.0 36 150 0.95
GpppAm 785.0 422.0 35 123 0.95
GpppAm 785.0 424.0 34 123 0.95
m7GpppA 785.0 407.9 37 103 0.98
m7GpppA 785.0 620.0 26 103 0.98
GpppG 787.1 424.0 38 160 0.94
GpppG 787.1 441.9 37 160 0.94
Gpppm6Am 799.0 423.6 34 126 1.05
Gpppm6Am 799.0 436.0 36 126 1.05
m7GpppAm/
m7Gpppm6A 799.0 422.0 37 126 0.98/1.08
m7GpppAm/
m7Gpppm6A 799.0 633.8 26 126 0.98/1.08
m7GpppG 800.9 635.9 28 120 0.97
GpppGm 801.0 423.9 36 119 0.94
GpppGm 801.0 438.0 38 119 0.94
m7Gpppm6Am 813.0 436.0 39 108 1.08
m7Gpppm6Am 813.0 438.0 35 108 1.08
m7GpppGm 815.0 438.0 39 112 0.96
m7GpppGm 815.0 517.9 37 112 0.96
ARCA 815.2 423.9 32 130 1.00
ARCA 815.2 451.9 32 130 1.00
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5common cap dinucelotides were detected in the tissues and T
cells; GpppAm,
m7GpppG and GpppGm were detected above
0.1 fmol µg−1 in all tissues; GpppA was present at approxi-
mately 0.5 fmol µg−1 in the heart and liver, but inconsistently
detected in other tissues; m7GpppAwas present in lowamounts
in all samples except for one of the brain samples, in which it
was not detected; and Gpppm6Am was very low in abundance
and only consistently detected in liver (figure 6b). Overall the
minor cap variants, which lack either cap guanosine N-7
methylation or first nucleotide ribose O-2 methylation,
constituted around 2–5% of the cellular caps.
Among the more common cap dinucleotides there were
tissue-specific differences (figure 6a,b). In most samples, the
abundances of caps with the first transcribed nucleotide A
and G were similar; however, in the heart, there were more
than twice as many caps with A as the first transcribed nucleo-
tide as there were with G as the first transcribed
nucleotide. This likely reflects differences in the heart transcrip-
tome, compared with other tissues analysed. The other major
difference in cap structure abundance between tissues was
the proportion of first nucleotide adenosine caps with the
m6A modification. All tissues had a greater concentration of
m7Gpppm6Am than
m7GpppAm, but the ratio of these two cap
structures varied considerably between tissues. The liver had
the lowest m7Gpppm6Am :
m7GpppAm ratio of 3.5. Brain, at
the other extreme, had an m7Gpppm6Am :
m7GpppAm ratio of
14.6 (figure 6c). These results indicated tissue-specific regu-
lation of the m6A cap methyltransferase, CAPAM, and/or the
demethylase FTO. To demonstrate that our method candetect changes in the mRNA cap structure following pertur-
bations in cap methyltransferase activity we reduced
CAPAM expression by transfection of siRNA in HeLa cells.
CAPAM knockdown was confirmed by western blotting
(figure 7a). As expected, CAPAM knockdown results in an
increase in m7GpppAm and a decrease in
m7Gpppm6Am
(figure 7b and table 4). In the control siRNA transfected
HeLa cells, there is about ninefold more m7Gpppm6Am than
m7GpppAm, whereas this ratio drops to about 1.2-fold when
CAPAM expression is repressed (figure 7c). Notably, the
amount of m7GpppGm which is not a CAPAM substrate or
product is very similar between the control and CAPAM
siRNA-treated cells. These findings demonstrate that short-
term regulation of a cap methyltransferase causes sufficient
changes in mRNA structures to be detectable by CAP-MAP.3. Discussion
Here, we report the development of CAP-MAP, a rapid,
sensitive and relatively direct method of mRNA cap analysis.
The benefit of CAP-MAP is that, following oligo dT-based
enrichment of mRNA and digestion, cap structures are ready
for LC–MS analysis. This simple preparation is possible
owing to the selectivity of the PGC column and unique tri-
phosphate-linked dinucleotide structure of the mRNA caps.
The small number of preparative steps means that the relative
proportion of cellular cap structures is likely to be faithfully
maintained during analysis.
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Figure 3. Elution profiles of 11 cap nucleotides on a PGC column. Chromatogram showing the differential separation of 11 cap nucleotides on a PGC column. MRM values
are indicated to the right of each chromatogram. In the lane containing m7GpppAm and
m7Gpppm6A the m7GpppAm elutes earliest.
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6From the cap structures which we investigated (those
with first nucleotide G or A), the major cap structures,
m7GpppGm,
m7GpppAm and
m7Gpppm6Am, were detected in
250 ng mRNA (oligo dT-purified) from tissue sources. Minor,
undermethylated cap structures were detected in 15 µg
mRNA. As reported by earlier studies, caps methylated onthe N-7 position of the terminal guanosine and O-2 position
of the first transcribed nucleotide ribose were the most
common across a range of tissue sources/cell types
[1,15,18,19]. However, in 2–5% oligo dT-purified transcripts,
a variety of incompletely methylated cap dinucleotide struc-
tures in which one or both methyl groups were absent were
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Figure 4. Detection of cap dinucleotides in serial dilution. (a) Peak area measurements from a serial dilution of synthetic cap dinucleotides. Slopes from linear
regression of these values were calculated to allow conversion between peak area and fmol (table 3). (b) Peak area measurements for GpppA from a serial dilution
of synthetic cap dinucleotides, provided as an example. (c) Table demonstrating overlap in product ions originating from m7GpppG and GpppGm. (d ) Detection of
m7GpppG across a dilution series. m7GpppG is detected with its unique m/z 800.9→ 635.9 precursor→ product ion transition, but it also contributes to the m/z
801.0→ 423.9 and 438.0 precursor→ product ion transitions shared with the isobaric dinucleotide GpppGm. The m/z 801→ 423.9 and 438 transition ion current
signals from m7GpppG can be back-calculated from the m/z 800.9→ 635.9 precursor→ product ion signal and subtracted from the total m/z 800.9→ 635.9
precursor→ product ion signal to allow quantification of GpppGm. (e) Compensation for shared ions between
m7GpppG and GpppGm.
m7GpppG and GpppGm
raw peak areas are shown and the GpppGm peak area after correcting for
m7GpppG forming product ions at m/z 423.9 and 438. Femtomoles of cap per µg
input mRNA are calculated using the linear fit between fmol and peak area (table 3). Each point represents a biological replicate.
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7detected. Demethylase activities which target the methyl
groups on theN-7 position of the cap guanosine or theO-2 pos-
ition of the first transcribed nucleotide ribose have not been
isolated from mammalian cells and therefore the undermethy-
lated structures are unlikely to be breakdown products. This
implies that either a certain amount of mRNA is processed
into polyadenylated transcripts in the absence of a completed
cap structure and/or the cap is completely removed, recapped
and partially methylated [45]. Undermethylated caps were
uncommon, typically making up less than 5% of cellular
mRNA caps, indicating either that they are efficiently con-
verted to their methylated forms and/or that they are
effectively removed by decapping enzymes including DXO
and NUDT16 [46,47].
The sequence of cap methylations is of mechanistic interest
when considering regulation of mRNA cap formation. The
cap0, cap1, cap2 notation, abbreviating m7GpppN, m7GpppNm,
m7GpppNmNm, respectively, can imply that guanosine N-7
methylation occurs prior to first nucleotide ribose O-2 methyl-
ation; however, to our knowledge, data have not been
presented to suggest an obligatory order to cap methylationsin mammalian cells. We detected both GpppNm and
m7GpppN cap structures in a variety of tissues, suggesting
that RNMT and CMTR1 can independently methylate the
RNA cap. This is consistent with in vitro assays investigating
the activity of these enzymes on GpppG caps and m7GpppG
caps [48,49]. Notably, CMTR1 binds directly to the RNAPII
C-terminal domain whereas RNMT interacts indirectly with
RNAPII predominantly via interactions with RNA and
RNAPII-associated proteins, which does not enforce or imply
an obligate order of action [50,51].
CAPAM/PCIF1, the enzyme catalysing first transcribed
nucleotide m6A methylation, has recently been identified and
characterized [9–12]. m6A methylation is the only cap methyl-
ation that has been demonstrated to be reversible, leading to
an interest in whether it may coordinate signalling events
with translation or transcript stability [25]. Consistent with
recent estimates of the abundance of the m7Gpppm6Am cap,
we found it to bemore abundant than m7GpppAm in all tissues
[9–12]. However, the ratio of m7Gpppm6Am to
m7GpppAm
varied between tissues with higher m7Gpppm6Am in heart
and brain and lower m7Gpppm6Am in liver and CD8 T cells.
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8This indicates that adenosine N-6 methylation by CAPAM or
demethylation by FTO is differentially regulated across these
tissues. CAP-MAP was able to detect a substantial decrease
in m7Gpppm6Am levels and an increase in
m7GpppAm in
HeLa cells following short-term knock down of CAPAM, illus-
trating its potential to investigate the effects of CAPAM and
FTO regulation on cellular cap structures.
Recently, an alternative LC–MSmethod for detectingmRNA
caps was reported by Wang et al. [52]. There are a number of
differences between our CAP-MAP approach and that of
Wang et al. to be considered when selecting a method of cap
analysis. Wang et al. extended their analysis to include a variety
of rare non-canonical metabolite mRNA caps, including NAD-
caps, which have only recently been described in mammalian
cells, and FAD-caps, UDP-Gluc-caps and UDP-GlucNAc-caps,
which were not previously observed in mammals [53]. Thus,
Wang et al.’s cap analysismethodologywill be critical for under-
standing the physiological functions of metabolite caps in
mammalian cells [54]. Since the interest of our laboratory centres
on capmethyltransferases, our analysis focused on dinucleotide
caps. The main advantage of our approach is that we quantify
capsdirectly fromoligodT-purifiedRNAdigestedwithnuclease
P1, whereas Wang et al. used an additional HPLC purification
step to separate cap structures from nucleotide monophos-
phates. This additional step increases the protocol length and
may result in some sample loss; this was carefully controlled
for byWang et al. by the use of heavy isotope-labelled standards
for each cap. DuringHPLCpurification of caps, sinceWang et al.
used a hydrophobic C18 column, the ion-pairing agent DBAA
was used to enable hydrophilic cap structures to interact with
the column. We wanted to avoid using an ion-pairing agent
because it is hard to remove and any remaining in the sample
following preparation causes ion suppression, thus reducing
MS sensitivity. In addition, because ion-pairing agents are diffi-
cult to completely remove from the analytical systems it is an
unpopular choice for our shared equipment. Therefore, our
CAP-MAP method may be appropriate for those who are
using shared equipment and are solely interested in detecting
(m7)GpppX(m) structures. Those interested in metabolite caps
and who have dedicated instruments may find the method
described by Wang et al. to be most useful.
There were some differences in the cap dinucleotide struc-
tures detected by our methods. We detected a range of
undermethylated caps, as discussed above, which were not
detected byWang et al.However,Wang et al.detected substantial
amounts ofm7Gpppm6A, similar in concentration tom7GpppAm,
in mouse liver and the human CCRF-SB cell line mRNA.
CAPAM was determined to have a 7.6-fold preference for
ribose O-2 methylated caps over ribose unmethylated caps, a
selectivity which would permit the formation of m7Gpppm6A
in vivo [10]. In previous analyses of HEK293T and MEL624
cells, m7Gpppm6A was not detected [9–12]. In CAP-MAP, we
readily detected synthetic m7Gpppm6A, but did not detect this
cap dinucleotide in liver, other mouse tissues or HeLa cells.
This could reflect either biological differences in the mRNA
cap structures present in our samples or differences in our separ-
ation and detection of m7Gpppm6A. In addition to the
methodological differences stated above, Wang et al. detected
cap dinucleotides in the positive ion mode, whereas we used
the negative ion mode; thus the product ions used to confirm
the identities of cap dinucleotides in our experiments are differ-
ent: we used product ions at m/z 422.0 and 633.8 to detect
m7Gpppm6A, whereas Wang et al. used a product ion at m/z
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9150. These differencesmaymodify the sensitivity of detection of
cap dinucleotides in the sample, affecting thresholds of
detection.
To conclude, as it is becoming more apparent that mRNA
cap methylation is a regulated process, a simple and sensitive
method for quantifying the mRNA cap structures present
in cells is required. Here, we present CAP-MAP, a rapid
and direct method for mRNA cap analysis by LC–MS. In
CAP-MAP, major cap dinucleotide variants are detected and
quantified with low-input mRNA (500 ng), which can rapidly
be recovered from cultured cells or tissue samples, and minor
cap dinucleotides can be detected using a larger quantity of
mRNA.4. Material and methods
4.1. Cap dinucleotide standards
Synthetic cap dinucleotide standards were either bought
from New England Biolabs (NEB) or synthesized. A list of the
cap dinucleotides and their sources is available in table 1.
Syntheses of dinucleotide cap analogues GpppGm,
GpppAm, Gppp
m6Am,
m7GpppGm,
m7GpppAm,
m7Gpppm6A,m7Gpppm6Am were performed from GDP or m
7GDP
and imidazolide derivatives of 20-O-methylguanosine 50-O-mo-
nophosphate (m2
0-OGMP), 20-O-methyladenosine 50-O-
monophosphate (m2
0-OAMP) and 6,20-O-dimethyladenosine 50-
O-monophosphate (m2
6,20-OAMP), respectively, according to the
methods reported previously [55,56]. The mononuclotide sub-
strates (m2
0-OGMP, m2
0-OAMP, m6AMP and m2
6,20-OAMP) were
prepared from the appropriate nuclosides (m2
0-OGuo, m2
0-
OAdo,m6Ado andm2
6,20-OAdo) by 50-O-phosphorylation accord-
ing to the procedures described earlier [55,57]. The intermediate
6-methyladenosine (m6Ado) was prepared from 6-chloropurine
riboside (Aldrich) according to Johnson et al. [58]. 20-O-Methyl-
ated intermediates m2
0-OGuo, m2
0-OAdo and m2
6,20-OAdo were
synthesized using methods described by Robins et al. [59].
4.2. Cap dinucleotide detection and relative
quantification by LC–MS
Eleven different cap dinucleotide standards were used to
optimize the LC–MS method for cap detection and quantifi-
cation. Cap nucleotide levels were measured using a TSQ
Quantiva mass spectrometer interfaced with an Ultimate
3000 Liquid Chromatography system (ThermoScientific),
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10equipped with a PGC column (HyperCarb 30 × 1 mm ID
3 µm; part no. C-35003–031030; Thermo-Scientific). Mobile
phase buffer A consisted of 0.3% (v/v) formic acid adjusted
to pH 9.15 with ammonia prior to a 1/10 dilution. Mobile
phase buffer B was 80% (v/v) acetonitrile. The column was
maintained at a controlled temperature of 45°C and was equi-
librated with 18% buffer B for 9 min at a constant flow rate of
0.04 ml min−1. Aliquots of 14 µl of each sample were loadedonto the column and compounds were eluted with a linear
gradient of 18–21% buffer B over 2 min, 21–40% buffer B
over 2 min, 40–60% buffer B over 10 min. The column was
washed for 4 min in 100% buffer B before equilibration in
18% buffer B for 9 min. Eluents were sprayed into the TSQ
Quantiva using an Ion Max NG ion source with the ion trans-
fer tube temperature at 350°C and vaporizer temperature at
60°C. The TSQ Quantiva was run in negative mode with a
Table 4. Summary of cap yields. Where a cap dinucleotide was not detected in one or more replicates this is indicated with n.d.
cap structure
mean and (s.d.) in fmol µg−1 mRNA for each cap structure
liver CD8 T cell heart brain HeLa + si-scrambled HeLa + si-CAPAM
m7GpppGm 15.18 (3.76) 18.78 (3.97) 12.74 (2.27) 15.41 (2.57) 194.43 (35.09) 175.60 (19.03)
m7Gpppm6Am 13.33 (2.79) 20.35 (3.26) 25.52 (4.17) 14.02 (3.47) 159.61 (29.11) 94.36 (12.56)
m7GpppAm 3.86 (0.80) 4.47 (0.73) 2.57 (0.34) 0.96 (0.19) 17.13 (1.69) 76.11 (7.44)
GpppAm 0.11 (0.02) 0.26 (0.24) 0.35 (0.13) 0.26 (0.03) n.d. n.d.
GpppGm 0.12 (0.01) 0.37 (0.13) 0.33 (0.13) 0.21 (0.08) n.d. n.d.
m7GpppG 0.27 (0.07) 0.28 (0.17) 0.17 (0.10) 0.23 (0.11) n.d. n.d.
m7GpppA 0.05 (0.02) 0.08 (0.02) 0.13 (0.12) n.d. n.d. n.d.
GpppA 0.51 (0.10) n.d. 0.54 (0.12) n.d. n.d. n.d.
Gpppm6Am 0.03 (0.01) n.d. n.d. n.d. n.d. n.d.
GpppG n.d. n.d. n.d. n.d. n.d. n.d.
m7Gpppm6A n.d. n.d. n.d. n.d. n.d. n.d.
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11spray voltage of 3500, Sheath gas 40 and Aux gas 10 and
sweep gas 2. Levels of the 11 cap nucleotides were measured
using MRM mode with optimized collision energies andradio-frequencies previously determined by infusing pure
compounds (table 1). A chemically similar cap standard
(ARCA (m7GO-3 mpppG)) (NEB) was used as an internal stan-
dard (table 1). A standard curve was prepared using
3–1000 fmol of all 11 cap nucleotides with 250 fmol internal
ARCA standard spiked into each sample. The standard
curve was run prior to running the experimental samples
using the same conditions, and was used to calculate the rela-
tive amount of the 11 cap nucleotides in each sample. One
blank was run between each sample to eliminate carry-
over. In one experiment, AMP was detected using m/z
346.0→ 134.2, 151.3, 211.1; these transitions were determined
using AMP from Sigma. Representative chromatograms from
each experiment are shown in electronic supplementary
material, figures S1–S7.
4.3. Preparing RNA from tissues
Mice were either C57Bl/6 J mice or control mice from our colo-
nies that are kept on aC57Bl/6 J background.Micewere housed
in the University of Dundee transgenic facility. Livers, brains
and hearts were snap-frozen in liquid nitrogen, ground in a
pestle and mortar and lysed in TRI Reagent (Sigma). RNA
was extracted according to the manufacturer’s protocol, includ-
ing theoptional centrifugationbefore theadditionof chloroform
to remove insoluble material. In addition, a second phenol–
chloroform extraction was performed on the aqueous phase
from the initial separation in TRI Reagent (ThermoFisher).
RNAwas dissolved in Hypersolv water (VWR) and quantified
using a nanodrop (ThermoFisher).
4.4. Preparing RNA from cell cultures
Cells were cultured in 5% CO2, 37°C. CD8 T cells were purified
from mouse lymph nodes using an easySep CD8 kit (Stemcell
Technologies) and activated on plate-bound anti-CD3 (clone
145–2C11; Biolegend) and anti-CD28 (clone 37.51; Biolegend)
antibodies in RPMI medium (Gibco/Thermofisher) with
20 ng ml−1 interleukin 2 (Novartis), 10% fetal calf serum
(FCS) (Gibco/Thermofisher), 50 mM 2-mercaptoethanol
(Sigma) and PenStrep (Thermofisher) for 5 days. Hela cells
royalsocietypublishing.org/journal/rsob
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12were grown in DMEM (Gibco/Thermofisher) with 10% FCS
and 5 U ml−1 penicillin-streptomycin (ThermoFisher). PCIF1-
directed siRNA smartpool or scrambled siRNA (Dharmacon)
was transfected using a Neon transfection system (Thermo-
fisher) using 1005 V × 35 ms × 2. CAPAM knockdown was
confirmed by western blotting with anti-PCIF1 (ab205016;
Abcam) and anti-actin (ab3280; Abcam) antibodies. RNAwas
prepared from cells as per the tissue samples, with the excep-
tion that cells were directly lysed in Tri-Reagent rather than
frozen and ground.
4.5. Preparing mRNA
For large-scale mRNA extractions, polyadenylatedmRNAwas
enriched using 100 µl oligo dT agarose beads (NEB) per mg
RNA. RNA was bound to the beads in binding buffer (1M
NH4OAc, 2 mMEDTA) for 5 min rotating at room temperature
andwashed once. RNAwas eluted in room temperaturewater,
filtered in SpinX (Corning) tubes to remove any beads, then
precipitated in 2.5 M NH4OAc and isopropanol, centrifuged
at 14 000 r.p.m. × 30 min and pellets washed in 75% ethanol.
To extract mRNA fromHeLa cell samples anmRNADirect
kit (ThermoFisher) was used. Magnetic oligo dT beads (40 µl)
were used per sample, but with the binding buffer and incu-
bation times indicated above. mRNA was digested with
9.5 units of Nuclease P1 (Sigma) in 20 mM NH4OAC pH 5.3for 3 h at 37°C. Then, 250 fmol of ARCA was added, and
LC–MS was carried out as described above.4.6. Analysis
Peak areas were determined for each transition for each cap
dinucleotide. Where there was more than one transition peak
on the chromatogram, the correct peakwas selected by its reten-
tion time relative to the ARCA internal standard and presence
of product ions in the ratio indicated by the synthetic standards.
The abundances of the various caps from mRNA were calcu-
lated by comparison with the dilution series of cap standards.
Conversion factors are listed in table 3. Statistical analysis and
plots were produced in Prism 5 (GraphPad Software).
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